U.S. Markets open in 16 mins
  • S&P Futures

    4,196.00
    -26.25 (-0.62%)
     
  • Dow Futures

    33,530.00
    -275.00 (-0.81%)
     
  • Nasdaq Futures

    14,100.50
    -65.00 (-0.46%)
     
  • Russell 2000 Futures

    2,258.70
    -25.80 (-1.13%)
     
  • Crude Oil

    70.61
    -0.43 (-0.61%)
     
  • Gold

    1,777.20
    +2.40 (+0.14%)
     
  • Silver

    26.10
    +0.25 (+0.96%)
     
  • EUR/USD

    1.1882
    -0.0028 (-0.2376%)
     
  • 10-Yr Bond

    1.5040
    -0.0070 (-0.46%)
     
  • Vix

    19.64
    +1.49 (+8.21%)
     
  • GBP/USD

    1.3859
    -0.0065 (-0.4643%)
     
  • USD/JPY

    110.2900
    +0.0590 (+0.0535%)
     
  • BTC-USD

    37,367.07
    -1,305.52 (-3.38%)
     
  • CMC Crypto 200

    924.01
    -45.86 (-4.73%)
     
  • FTSE 100

    7,046.60
    -106.83 (-1.49%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

InspireMD Announces Stock Exchange Listing Transfer to Nasdaq

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Ticker to remain NSPR

TEL AVIV, Israel, May 10, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company’s shares have been approved for listing on The Nasdaq Capital Market (“Nasdaq”). Trading is expected to begin on May 21, 2021, under the symbol NSPR on the Nasdaq.

InspireMD CEO Marvin Slosman commented, “We believe that moving to the Nasdaq Capital Market is a strategically important change that places us in the company of our peers and allows us greater access to a wider set of investors, thereby enabling us to build our fundamental base of investors. InspireMD is a stronger company today than ever before, and I am proud of the extraordinary efforts of our expanding team in creating an exciting future for our company. We are extremely pleased to now be a part of the Nasdaq exchange and value our new relationship.”

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.

As of May 21, 2021, InspireMD’s common stock will be quoted on the Nasdaq under the ticker symbol NSPR.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com

CORE IR
investor-relations@inspiremd.com